Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Meg Rivers is the former senior editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Podcasts

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines.

Drug Solutions Podcast: Developing Oral Recombinant Vaccines

Articles

Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.

Piramal Pharma Solutions Expands and Upgrades UK Manufacturing Facilities

China-based CDMO Asymchem acquires US-based chemical technology company Snapdragon. 

Asymchem Acquires Snapdragon Chemistry

The European Patent Office has granted another patent to Salipro Biotech,  covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

European Patent Office Grants Further Patent to Salipro Biotech

Domainex is collaborating with Parkinson’s UK for the development of small-molecule therapies targeting the neuroinflammation that is associated with Parkinson’s disease.

Domainex Collaborates with UK Charity to Develop Therapies for Parkinson’s

Pharming Group has announced positive results from the Phase II/III study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). 

Pharming Reveals Positive Trial Results for Leniolisib Study

Videos

In this episode of Drug Digest, Chris Spivey, editorial director, and Meg Rivers, senior editor, dive into APIs, excipients, and formulation advances, specifically pairing the right APIs and excipients for optimizing formulations.

Drug Digest: Pairing the Right APIs and Excipients for Optimizing Formulations

Yeli Zhang is North America Technical Manager IFF Pharma Solutions, Wilmington, DE.

Elizabeth Tocce is associate application development engineer, Dupont.

Holly Bertrand is Research Investigator IFF Pharma Solutions, Wilmington, DE.

Kevin McIntyre is Laboratory Supervisor, IFF Pharma Solutions, Wilmington, DE.

Fernanda Onofre, Americas Regional Applications Leader, IFF Pharma Solutions, Wilmington, DE.

Amina Faham is Global Director of Applications Development & Innovation; IFF Pharma Solutions, Wilmington, DE.

In this study, researchers evaluated the colloidal microcrystalline cellulose (cMCC) suspending agent—a co-processed material of microcrystalline cellulose and sodium carboxymethyl cellulose (NaCMC)—by using a representative pharmaceutical-grade commercial version of cMCC.

Polymer Influence on the Rheological Properties of Co-Processed Microcrystalline Cellulose and Sodium Carboxymethylcellulose

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants. 

What’s Next for COVID-19 Vaccines and Variants?

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Interest in natural phytochemicals or synthetic derivatives of cannabinoids has risen.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development